# Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

> **NCT03233139** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Regeneron Pharmaceuticals** · enrollment: 146 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Ipilimumab
- **DRUG:** Platinum-doublet chemotherapy
- **DRUG:** Gemcitabine
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel
- **DRUG:** Fianlimab

## Key facts

- **NCT ID:** NCT03233139
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-21
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03233139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03233139, "Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03233139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*